PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
18.47
+0.12 (0.65%)
Feb 21, 2025, 4:00 PM EST - Market closed
PureTech Health Employees
PureTech Health had 90 employees as of December 31, 2023. The number of employees decreased by 21 or -18.92% compared to the previous year.
Employees
90
Change (1Y)
-21
Growth (1Y)
-18.92%
Revenue / Employee
$5,200
Profits / Employee
-$916,289
Market Cap
429.78M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
PRTC News
- 10 days ago - PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform - Business Wire
- 27 days ago - PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine - Business Wire
- 6 weeks ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) - Business Wire
- 6 weeks ago - PureTech Appoints UBS as UK Corporate Broker - Business Wire
- 2 months ago - PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial - Business Wire
- 2 months ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 - Business Wire
- 2 months ago - PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting - Business Wire
- 3 months ago - PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors - Business Wire